The proposed application represents a comprehensive plan of three projects to improve the capacity of existing tests for pancreatic cancer, and to validate novel biomarkers discovered as part of collaborative efforts during the previous phase of the EDRN. The first project further develops a broad based diagnostic test for pancreatic cancer that enhances the CA19-9 test and incorporates elements of early detection of cancer by detecting autoantibodies to tumor specific glycopeptide structures found on mucins. The earliest premalignant and malignant lesions in the pancreas express MUCI, MUC4, MUC5ac, MUC16, and MUC17 with truncated O-linked structures attached (Tn, sialyl Tn, T) but may not produce a sufficient amount to be detected in serum. Instead, autoantibodies to these specific structures are produced at sufficiently high concentrations to be detected. As lesions progress mucins are detected in circulation, initially as immune complexes with the autoantibodies, and in later stages in the absence of immune complexes. This overall hypothesis will be tested by developing a set of three integrated tests for serum: a test that quantifies autoantibodies, a test that quantifies immune complexes, and a test that quantifies circulating mucins for both oligosaccharide and core protein (on the same molecule). A complementary study in collaboration with Dr. Sam Hanash will identify non-mucin proteins that carry Tn and sialyl Tn antigens and evaluate autoantibodies to these proteins. The second project led by Dr. Surinder Batra proposes to further develop a novel analytical test that shows enhanced sensitivity for detection mucin type glycoprotein (which can be difficult to detect using conventional techniques) using surface enhanced Raman spectroscopy (SERS). This technique will be used to develop an assay for multiple biomarkers in serum. The third project, led by Dr. Schmittgen and in collaboration with Dr. Hollingsworth, will undertake discovery of potential miRNA biomarkers in plasma and urine of patients with different stages of pancreatic cancer and evaluate the prognostic utility for patients with resected pancreatic cancer of evaluating the tissue expression of a set of microRNAs that are associated with early metastasis of pancreatic cancer.

Public Health Relevance

The early detection of pancreatic cancer would increase the percentage of patients eligible for curative resection, and thereby significantly improve the fraction and longevity of survivors of this disease, which is among the most lethal of cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01CA111294-10S1
Application #
9133736
Study Section
Special Emphasis Panel (ZCA1-SRLB-C (M1))
Program Officer
Rinaudo, Jo Ann S
Project Start
2004-09-27
Project End
2016-06-30
Budget Start
2014-07-01
Budget End
2016-06-30
Support Year
10
Fiscal Year
2015
Total Cost
$197,326
Indirect Cost
$66,036
Name
University of Nebraska Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Sutaria, Dhruvitkumar S; Jiang, Jinmai; Azevedo-Pouly, Ana Clara P et al. (2017) Expression Profiling Identifies the Noncoding Processed Transcript of HNRNPU with Proliferative Properties in Pancreatic Ductal Adenocarcinoma. Noncoding RNA 3:
Kaur, Sukhwinder; Smith, Lynette M; Patel, Asish et al. (2017) A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study. Am J Gastroenterol 112:172-183
Karmakar, Saswati; Seshacharyulu, Parthasarathy; Lakshmanan, Imayavaramban et al. (2017) hPaf1/PD2 interacts with OCT3/4 to promote self-renewal of ovarian cancer stem cells. Oncotarget 8:14806-14820
Krishn, Shiv Ram; Kaur, Sukhwinder; Sheinin, Yuri M et al. (2017) Mucins and associated O-glycans based immunoprofile for stratification of colorectal polyps: clinical implication for improved colon surveillance. Oncotarget 8:7025-7038
Kumar, Sushil; Cruz, Eric; Joshi, Suhasini et al. (2017) Genetic variants of mucins: unexplored conundrum. Carcinogenesis 38:671-679
Lakshmanan, Imayavaramban; Salfity, Shereen; Seshacharyulu, Parthasarathy et al. (2017) MUC16 Regulates TSPYL5 for Lung Cancer Cell Growth and Chemoresistance by Suppressing p53. Clin Cancer Res 23:3906-3917
Muniyan, Sakthivel; Haridas, Dhanya; Chugh, Seema et al. (2016) MUC16 contributes to the metastasis of pancreatic ductal adenocarcinoma through focal adhesion mediated signaling mechanism. Genes Cancer 7:110-124
Joshi, Suhasini; Cruz, Eric; Rachagani, Satyanarayana et al. (2016) Bile acids-mediated overexpression of MUC4 via FAK-dependent c-Jun activation in pancreatic cancer. Mol Oncol 10:1063-77
Huang, Huocong; Svoboda, Robert A; Lazenby, Audrey J et al. (2016) Up-regulation of N-cadherin by Collagen I-activated Discoidin Domain Receptor 1 in Pancreatic Cancer Requires the Adaptor Molecule Shc1. J Biol Chem 291:23208-23223
Fink, Darci M; Steele, Maria M; Hollingsworth, Michael A (2016) The lymphatic system and pancreatic cancer. Cancer Lett 381:217-36

Showing the most recent 10 out of 176 publications